Last updated: February 25, 2026
What excipients are used in ALEVE PM?
ALEVE PM contains two primary active ingredients: naproxen sodium and diphenhydramine hydrochloride. Its formulation balances these with several excipients designed for stability, bioavailability, and patient acceptability. The excipients include:
- Microcrystalline cellulose: A filler and disintegrant.
- Magnesium stearate: A lubricant facilitating tablet manufacturing.
- Starch: Serves as a disintegrant.
- Polyethylene glycol (PEG): Acts as a binder and stabilizer.
- Colorants: To provide the product's trademark appearance.
- Preservatives: To prevent microbial growth.
The specific excipient profile is optimized for rapid disintegration and effective absorption, ensuring effective analgesic and sedative effects.
How do excipient choices impact ALEVE PM's formulation and performance?
Excipients influence drug stability, release profile, palatability, and manufacturing efficiency:
- Disintegrants (microcrystalline cellulose, starch) speed disintegration, enabling rapid onset.
- Lubricants (magnesium stearate) prevent tablet sticking in manufacturing.
- Binders (PEG) improve tablet cohesion, stability during storage.
- Colorants and flavorings improve patient compliance.
Strategic excipient selection minimizes formulation shelf-life issues and enhances bioavailability, especially critical given the combination of a non-steroidal anti-inflammatory drug (NSAID) and antihistamine.
What are the commercial opportunities driven by excipient strategies?
1. Formulation Differentiation
Optimizing excipient profiles can produce faster disintegration, higher stability, or improved taste, differentiating ALEVE PM from competitors.
2. Patent Extension and Market Exclusivity
Innovative excipient use can support formulation patents, extending exclusivity periods. Patent filings on specific excipient combinations or processing methods can delay generic entry.
3. Supply Chain Optimization
Sourcing high-quality, cost-effective excipients may reduce manufacturing expenses and improve margins. Contract manufacturing organizations (CMOs) with bulk excipient capabilities may offer scale advantages.
4. Regulatory Advantage
Well-characterized excipient profiles facilitate faster regulatory approval by demonstrating stability and safety. Using FDA-accepted excipients reduces approval hurdles.
5. New Formulation Variants
Developing extended-release, flavored, or lower-dose versions leveraging excipient technology expands market reach.
6. Intellectual Property (IP) Portfolio Expansion
Patents related to novel excipient combinations or processing methods create licensing opportunities and protect against generic competition.
How do competitive landscape and market trends influence excipient strategy?
- The analgesic and sleep aid markets face increasing pressure for formulations with improved patient experience.
- Innovations in excipients, such as taming taste or enabling lower excipient loadings, align with consumer preferences.
- The rising demand for generic versions post-patent expiry. Patent strategies based on excipient innovations can delay generics.
What are key considerations for excipient selection and commercialization?
- Safety profile of excipients, complying with FDA and EMA standards.
- Compatibility with active ingredients to prevent interactions.
- Cost-effectiveness for large-scale manufacturing.
- Scalability and supply chain resilience, especially during global disruptions.
- Regulatory documentation and traceability for excipient sources and specifications.
Conclusion
ALEVE PM’s formulation relies on carefully selected excipients to optimize performance, stability, and patient acceptance. Strategic innovations in excipient use can expand market opportunities through formulation differentiation, patent protection, and cost optimization. Staying abreast of regulatory changes and consumer preferences guides effective excipient strategy development.
Key Takeaways
- Excipients in ALEVE PM support rapid disintegration, stability, and manufacturing efficiency.
- Strategic excipient choices can lead to patent protections and market exclusivity.
- Formulation innovations enable product differentiation and address consumer demand for improved experiences.
- Cost management and supply chain resilience are critical in excipient sourcing.
- Regulatory compliance and safety are fundamental in excipient selection and commercialization.
FAQs
Q1: Can excipient modifications affect the drug's regulatory approval?
Yes. Changes that alter stability or release profiles may require supplemental filings and additional testing.
Q2: Are there opportunities for natural or plant-based excipients in ALEVE PM?
Potentially. Natural excipients can appeal to consumers seeking "clean label" products but must meet safety, stability, and regulatory standards.
Q3: How does excipient choice influence the shelf life of ALEVE PM?
Excipients affect moisture retention, chemical stability, and disintegration. Proper selection extends shelf life and maintains efficacy.
Q4: What trends are influencing excipient innovation in over-the-counter (OTC) drugs?
Taste masking, allergen reduction, and enhanced bioavailability are key drivers in OTC excipient innovation.
Q5: How can excipient patents impact generic entry?
Patent protection on excipient combinations or processing methods can delay generic versions, maintaining market share for innovator products.
References
[1] Food and Drug Administration. (2022). Inactive Ingredient Database. Retrieved from https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
[2] European Medicines Agency. (2021). Excipients in the Label and Package Leaflet of Medicinal Products. Retrieved from https://www.ema.europa.eu/en/about-us/how-we-work/regulation/clinical-trials/excipients-medical-products
